Consistent with a prominent role of YAP in therapeutic response, elevated YAP expression is a biomarker of poor response to TT in patients with BRAF-mutant tumors and combined YAP and MAPK inhibition is synthetically lethal in BRAF- and RAS-mutant tumor types including melanoma through synergistic induction of apoptosis [66]. The gene discussed is BRAF; the disease is melanoma.